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Abstract
Over the past ten years the incidence of pertussis in the United States (U.S.) has risen
steadily, with 2012 seeing the highest case number since 1955. There has also been a shift
over the same time period in the age group reporting the largest number of cases (aside
from infants), from adolescents to 7–11 year olds. We use epidemiological modelling and a
large case incidence dataset to explain the upsurge. We investigate several hypotheses for
the upsurge in pertussis cases by fitting a suite of dynamic epidemiological models to inci-
dence data from the National Notifiable Disease Surveillance System (NNDSS) between
1990–2009, as well as incidence data from a variety of sources from 1950–1989. We find
that: 1) the best-fitting model is one in which vaccine efficacy and duration of protection of
the acellular pertussis (aP) vaccine is lower than that of the whole-cell (wP) vaccine, (effica-
cy of the first three doses 80% [95% CI: 78%, 82%] versus 90% [95% CI: 87%, 94%]), 2) in-
creasing the rate at which disease is reported to NNDSS is not sufficient to explain the
upsurge and 3) 2010–2012 disease incidence is predicted well. In this study, we use all
available U.S. surveillance data to: fit a set of mathematical models and determine which
best explains these data and determine the epidemiological and vaccine-related parameter
values of this model. We find evidence of a difference in efficacy and duration of protection
between the two vaccine types, wP and aP (aP efficacy and duration lower than wP). Future
refinement of the model presented here will allow for an exploration of alternative vaccina-
tion strategies such as different age-spacings, further booster doses, and cocooning.
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Author Summary
Over the past ten years the incidence of pertussis in the United States (U.S.) has risen
steadily, with 2012 seeing the highest case number since 1955. There has also been a shift
over the same time period in the age group reporting the largest number of cases (aside
from infants), from adolescents to 7–11 year olds. We investigate several hypotheses for
the upsurge in pertussis cases by fitting a suite of epidemiological models to incidence data
from the National Notifiable Disease Surveillance System (NNDSS) between 1990–2009.
We find that: 1) the best-fitting model is one in which the vaccine efficacy and duration of
protection of the acellular pertussis vaccine is lower than that of the whole-cell vaccine, 2)
increasing the rate at which disease is reported to NNDSS is not sufficient to explain the
upsurge and 3) 2010–2012 disease incidence is predicted well. These results demonstrate
that the resurgence in pertussis in the U.S. can be explained by past changes in vaccination
policy. However, our findings suggest that the efficacy of the currently-used acellular vac-
cine is not much lower than that of the whole-cell vaccine, and booster doses may be suffi-
cient to curtail epidemics while vaccine research continues.
Introduction
In 2012, the United States experienced the highest number of reported pertussis cases since
1955, shortly after the introduction of vaccine in the 1940s [1–3]. This upsurge occurred in the
context of steadily rising reported disease from the early-1980s [4], despite the maintenance of
high vaccination coverage levels (>90%) [5]. Pertussis remains a major cause of childhood
mortality world-wide, responsible for 195,000 deaths in 2008 [6]. A vaccine for the disease was
developed in 1942 in the U.S., and was included and administered as a killed whole-cell compo-
nent of the diphtheria/tetanus/pertussis (DTP) combination vaccine.
Following introduction of vaccination, the reported disease incidence in the U.S. declined
from 150 cases per 100,000 per annum prior to 1940, to the point of near elimination in the
mid-1970s (0.5 reported cases per 100,000)[4] (Fig 1). Due to the possible reactogenicity of the
whole-cell pertussis component of the DTP vaccine, acellular pertussis (aP) vaccine was devel-
oped as a replacement in 1991 (DTP became DTaP). This new vaccine was administered to
children in 1992 [7,8] and then phased into the infant immunization schedule beginning in
1997 [9,10], following approval by the U.S. Food and Drug Administration (FDA) and recom-
mendations by the U.S. Advisory Committee on Immunization Practices (ACIP).
Over the past 30 years, reported pertussis incidence in the U.S. has been steadily increasing
(Fig 1). Even accounting for this steady upward trend, which some have attributed to improved
surveillance and diagnostics [11,12], case numbers during 2004–2012 were notably high and
many state public health departments reported outbreaks during these years. During the two
most recent of these outbreaks, the worst-hit states were California (in 2010) [2,3] and Wash-
ington (in 2012) [13] with case counts unmatched since the mid-1940s. While the 2004–2005
outbreak was characterized by an increase in the number of cases among adolescents (10–20
year olds), as well as a less-pronounced increase across all ages, the most recent outbreaks have
seen many more cases among 7–10 year olds and young adolescents (11–13 year olds) along
with an overall increase in case numbers [2].
A number of explanations have been put forward for the increase in disease that has been
observed, particularly for the outbreaks of the past 10 years [11,14–19]. These include: 1) The
evolution of the circulating bacteria away from the targets of vaccine antigens; 2) A decline in
vaccine coverage levels; 3) a change in vaccine efficacy (VE), and/or duration of protection due
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to the shift to the acellular vaccine; or a specific lot of manufactured vaccine with lower efficacy;
4) The decline of natural boosting, through reduced exposure to naturally circulating pertussis
bacteria, as a result of years of successful mass-vaccination; 5) An increase in disease reporting
rates (e.g. due to improved diagnostics and surveillance) [20,21].
We examine these possible explanations using a population dynamic model representing in-
fection with Bordetella pertussis in an age-structured population. We fit the output of this
model to 20 years of age-stratified incidence data from the National Notifiable Diseases Sur-
veillance System (NNDSS). The model includes both vaccine and naturally-induced immunity
(with both of these sources of protection waning over time), the current vaccination schedule
administered to the population, an estimate of the underreporting of disease, and a decreased
infectiousness of those who have experienced greater than one infection.
Results
Eight different (nested) models were fitted to the NNDSS incidence data (Table 1). The most par-
simonious (best fitting) model, Model 8, has a difference in efficacy and duration of protection
between the whole-cell and acellular vaccines, and a difference between the duration of protection
of whole-cell vaccine and natural infection (Table 1). Model 5, in which the duration of protec-
tion for whole-cell vaccine and natural infection is the same, has a slightly lower DIC value, but is
very close to Model 8, and these two models are almost interchangeable in terms of their parame-
ter values. Further details of the candidate models are provided in the Supporting Information.
The model reproduces the trends in the NNDSS incidence data up to 2009; running the
model forward over another three years shows a continued correspondence with observed inci-
dence trends (Fig 2). A large proportion of forward simulations (>50%) show an upsurge in in-
cidence around 1990, a phenomenon that is not recorded in the data. However, the mean of
the model-predicted incidence remains much closer to the data, albeit with a large range
of uncertainty.
Fig 1. Incidence of disease and vaccination coverage in the United States. The time varying incidence of
disease in the US, summed over all ages, between 1950 and 2009, annotated for significant events relating
to vaccination policy. The blue solid line illustrates the DTP3 (first three DTP doses) vaccine coverage level
over time.
doi:10.1371/journal.pcbi.1004138.g001
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Fig 3 illustrates the age distribution of incident cases every two years from 1994–2012, for
Model 8. Several features of the NNDSS data are reproduced by the model: 1) an overall rise in
disease cases throughout the observed period; 2) an adolescent peak in the incidence curve for
most of the years post-1995; 3) a gradual rise in cases among 5–10 year olds from 2006, form-
ing a peak which is comparable in size with the adolescent peak by 2008.
In 2002, the dominant peak in incidence is among adolescents but another smaller peak
emerges among infants. This smaller peak moves forward one year at a time, growing in mag-
nitude until 2006 when the two peaks are of similar size. By 2008, the cohort of individuals
Table 1. Descriptions of the nested models that were fitted to the NNDSS incidence data.
Model Description DIC
1 Protection duration of whole cell vaccine same as natural infection; acellular vaccine
same as whole-cell
-9720
2 Protection duration of whole cell vaccine same as natural infection; different efﬁcacy for
acellular vaccine
-9570
3 Protection duration of whole cell vaccine same as natural infection; different protection
duration for acellular vaccine;
-9250
4 Protection duration of whole cell vaccine different from natural infection; acellular vaccine
same as whole-cell
-9800
5 Protection duration of whole cell vaccine same as natural infection; protection duration
and efﬁcacy different for acellular vaccine
-8422
6 Whole cell vaccine protection duration different from natural infection; different efﬁcacy for
acellular vaccine
-9183
7 Whole cell vaccine protection duration different from natural infection; different protection
duration for acellular vaccine
-9230
8 Whole cell vaccine protection duration different from natural infection; protection duration
and efﬁcacy different for acellular vaccine
-8417
The mean posterior values of the Deviance Information Criterion (DIC) of the models are given in the
rightmost column.
doi:10.1371/journal.pcbi.1004138.t001
Fig 2. Incidence of disease in the United States, compared with modeled values. The time varying
incidence of disease cases in the model and the US data (log scale) after 1990. The black dots are US
disease incidence data, and the shaded regions represent the credible intervals (50% and 95%) obtained
through model parameter estimation of model 8. The model has been run beyond the time over which it was
trained to illustrate its continued correspondence with the 2010–2012 data (red crosses).
doi:10.1371/journal.pcbi.1004138.g002
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immediately following the shift in vaccine efficacy have advanced to become 10 years of age
and they constitute the 'wavefront' of a swell of new disease. The two plots for 2010 and 2012
are included to illustrate that the model continues to correspond well with the age-distribution
of disease beyond the time period for which it was fitted (i.e. beyond 2009). Note that the corre-
spondence between these ‘predicted’ distributions of disease with age was not quantitatively de-
termined, due to the complexity of the total likelihood used for model-fitting, but these
distributions continued to capture the main features of the disease profile, namely: a) a rising
overall incidence; b) the highest peak of disease among infants; c) a growing adolescent peak
moving up in age with each advancing year.
The best-fitting model incorporates a drop in vaccine efficacy and a rise in the vaccine-protec-
tion waning rate from the whole cell to acellular vaccine. Both the change in the per dose efficacy
and the duration of protection change appreciably between vaccine types. Table 2 shows the esti-
mated mean and 95% confidence intervals (CI) of the efficacies of the first three doses, consid-
ered together, and the fourth and fifth doses (the probability of fully protective seroconversion).
Estimates of the epidemiological parameters are shown in Table 2. The basic reproduction
number, R0, was estimated to be 11 [95% CI: 9.9, 11.5], slightly lower than some previous esti-
mates [18]. Secondary and subsequent infections (those which are experienced by individuals
who retain some level of immune protection, whether due to vaccination or infection-induced
immunity) are found to be 32% [95% CI: 29%, 35%] as infectious as primary infections and
these individuals are found to be 17% [95% CI: 14%, 23%] as susceptible to infection as infec-
tion-naïve individuals.
The disease reporting rate is included in the model as a fraction of the infected cases experienc-
ing primary infection who will be symptomatic and captured by NNDSS surveillance. We find
that the best-fitting model does not require a change in the reporting rate to reproduce the major
Fig 3. Cross-sectional incidence of disease over age of population. Annual age-dependent (to age 30 years) incidence of pertussis disease cases for
the years 1994–2012 in 2 year intervals. Gray shaded envelopes indicate 50%, 90%, 95%, and 99% credible intervals from the model parameter and
uncertainty estimation. Black points (1994–2008) indicate disease incidence data collected by the NNDSS. The red crosses on the 2010 and 2012 plots also
represent NNDSS incidence data; however, the model was not fitted to these data and so model outputs represent out-of-sample predicted age-dependent
incidence curves.
doi:10.1371/journal.pcbi.1004138.g003
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trends in the data. The reporting rate is estimated at 6% [95% CI: 0.1%, 22%] with the wide credi-
ble intervals suggesting that a gradual change in reporting over time may not be precluded, even if
a step change is not supported. A gradual change in reporting is consistent with the uptake of
more sensitive diagnostic methods as well as greater awareness of pertussis in recent years.
Fig 4 shows the results obtained by simulating the case-control study conducted in 2010 by
Misegades et al [22]. We demonstrate that, in successive ages beyond when the final vaccine
dose is administered, there is a decline in the 95% credibility envelope of the model-based VE
estimates (gray-shaded region): the bottom of this envelope declines more rapidly than mea-
sured for the California study. The curve lying above the shaded region illustrates the results of
a hypothetical VE study if it had been conducted in 1990, the pre-acellular era. It can be seen
that VE declines more slowly in this case.
Discussion
We have shown that relatively small differences in the per-dose vaccine efficacy and duration
of protection between acellular and whole-cell vaccines is sufficient to explain the recent up-
surge in pertussis in the United States. These differences caused a shift in the age distribution
of pertussis disease incidence: the adolescent peak in years prior to 2006 shifted to a younger
age group (5–10 year olds) post-2006. This explanation for pertussis disease dynamics is in
broad agreement with case-control and retrospective cohort studies showing that vaccine-in-
duced immunity wanes faster than previously thought [22–24].
The average duration of protection we estimate for acellular vaccine is shorter than the es-
sentially lifelong protection we estimate for both whole-cell vaccination and natural infection;
however our estimate of the acellular protection duration is around 50 years, which is longer
than might be expected from published VE studies [22,23]. Since our calculated waning rate is
Table 2. Parameter estimates for the best-fitting model, Model 8 (models outlined in Table 1).
Parameter description Value
Vaccine efﬁcacies & waning
Whole-cell
Vaccine efﬁcacy of 1st 3 doses/4th/5th dose 90% [87%, 94%]
Rate of loss of whole-cell vaccine immunity 3x10-5yr-1 [2x10-6, 2x10-4] i.e. essentially
lifelong
Acellular
Vaccine efﬁcacy of 1st 3 doses/4th/5th dose 80% [78%,82%]
Rate of loss of acellular vaccine immunity 0.018yr-1 [0.015, 0.020] i.e. average of
approx. 50 yrs protection
Tdap
Vaccine efﬁcacy As acellular
Epidemiological Parameters
Basic reproduction number, R0 11.0 [9.9, 11.5]
Rate of loss of natural immunity 3x10-5yr-1 [2x10-6, 2x10-4] i.e. essentially
lifelong (as for whole-cell)
Relative susceptibility of individuals to subsequent infection
(with reference to naïve individuals)
32% [29%, 35%]
Relative infectiousness of individuals with subsequent
infection (with reference to primary-infected individuals)
17% [14%, 23%]
Year of reporting rate change None
Mean reporting rate prior to change 6.0% [0.1%, 22%]
Mean reporting rate after change n/a
doi:10.1371/journal.pcbi.1004138.t002
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an average over the whole population, this means some individuals will re-enter the susceptible
pool more quickly than others. By simulating a prospective VE study, we find that even a small
increased flow into the susceptible pool is sufficient to result in a strong signal of declining VE
following the final vaccine dose (see Figs 4 and 5 and [22]). The efficacy values implied here for
the full acellular vaccine regimen (i.e. 5 doses) are consistent with those estimated in the acellu-
lar pertussis vaccine (APERT) trial [25], lending further weight to the correspondence of our
model with the broad range of data. Furthermore, VE values for individuals with mixed acellu-
lar and whole-cell vaccine histories are consistent with a recent Australian report of disease
rates and linked vaccination histories [26].
While our analysis does not preclude the possibility of a rise over time in the rate of report-
ing (or detection) of cases of disease, such a rise is not necessary to explain recent patterns in
pertussis incidence. Our estimate of case reporting rates (approximately 6%) is in line with a re-
cent multi-country analysis [20], but has wide 95% credible intervals. Hence, progressive
changes in disease reporting, such as those expected by more sensitive diagnostic testing (e.g.
PCR) or a greater awareness of pertussis among patients and physicians, is within the scope of
our model. Further work with this model could investigate published reporting trends more
closely [11,20,21,27,28].
Our analysis sheds light on other, previously uncertain, aspects of pertussis epidemiology.
First, we estimate R0 to be in the range of 9–12 which is closer to the values found by previous
mathematical models [29,30] than the often-quoted range of 12–17 [31]. Such values do not
rule out elimination at high enough vaccination coverage levels. Second, previous recipients of
vaccine whose protection has waned are estimated to be 32% as susceptible to infection as in-
fection-naïve individuals and, if infected, these individuals are estimated to be 17% as infectious
as primary infections in immunologically naïve individuals. These numbers suggest that adults
and adolescents may be an important reservoir of infection. Third, the most parsimonious
model with a good fit to the data suggests that the duration of immunity generated by the
whole-cell vaccine is nearly equivalent to that induced by natural infection.
Fig 4. Case-control study results compared with modeled values. Vaccine Effectiveness (VE) as
measured in the case-control study of Misegades et al [22] from 2010 in California (black crosses) compared
with VE values generated by simulations of the case-control study using the model fitted to the incidence and
these VE data (gray region). The gray shaded region represents the 95% credible interval of the model
outputs. The dotted curve lying above the 2010 data and simulations was calculated by simulating a 1990
case-control study, and shows significantly slower waning of the VE value.
doi:10.1371/journal.pcbi.1004138.g004
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Our explanation for the upsurge and the age-shift in disease incidence differs from other re-
cent model-based studies [14,15]. We find a 'hypersensitive' boosting model [14] to be too un-
stable to mimic the steady post-1970s rise in disease; the incidence of disease for that model
shows a large amplitude oscillatory behaviour. Population age-dependent contact patterns
alone also appear to be insufficient to capture recent changes in U.S. incidence of disease [15].
Declines in vaccination coverage and the evolution of the circulating bacteria would lead to ris-
ing disease but not the changing age-distribution, although the recent discovery of pertactin-
negative (or other genetic) variants may be playing a role in the vaccine efficacy decline we
have found [32,33]. Changes in age-dependent disease reporting could mimic observed inci-
dence patterns, of course, but such models would lack the simplicity of ours.
Future refinement of the model presented here will allow for an exploration of alternative vac-
cination age-spacings for the five-dose childhood schedule, investigation into the effects of fur-
ther booster doses (for example, decennially to adults) and cocooning vaccination strategies
designed to protect infants who are most vulnerable to severe disease [22]. Further data collection
will help to narrow uncertainties in the model, for example, the range of R0 and, the infectious-
ness of those who have been previously infected, both relevant to control strategies. Alternative
model structures capturing the development and waning of immunity and boosting of immunity
may be contributing to discrepancies between the outputs of our best-fitting model and the avail-
able data, such as an overestimate of the incidence peak in adolescents after 2008 (Fig 3), and
signs of a model underestimate of the overall incidence (Fig 2). Future work should attempt to in-
corporate the full range of possibilities for modeling boosting and immunity e.g. using the
Fig 5. Epidemiological model diagram. The compartmental model for pertussis infection and disease
used, modified from the basic model of Aguas et al [44]. There are two infected compartments for primary (I1)
and secondary (or higher) infection (I2). We assume that surveillance systems only capture those who are
experiencing primary infection. Once an individual has recovered from primary or secondary infection,
induced immunity may wane, whereupon they will re-enter the susceptible state. Rates of flow between
compartments are defined in Table 3.
doi:10.1371/journal.pcbi.1004138.g005
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proposed model of Lavine et al. [14], as well as mixing matrix data that are as locally-specific as
possible, following the work of Rohani et al. and Riolo et al. [15,34]. Clearly, the use of a mixing
matrix from Great Britain is not ideal for the U.S. but was all that was available at the time of
writing. In addition, fitting our model to data from the U.S. aggregates the incidence from a large
number of more spatially localized epidemics, which may not be completely synchronized; this
means that, while our model is convincing, it tends to describe phenomena such as the ‘cohort ef-
fect’ and peaks in incidence more sharply than the data. Future work should focus on modeling
local outbreaks and endemic pertussis with high spatial resolution, following Rohani et al. and
Choisy et al. [35,36]. More intricate modeling frameworks, such as individual-based modeling,
are also promising directions for future work, given their ability to represent human behavioural
dynamics, which could be a major local contributor to vaccine uptake or refusal [37].
A further important step for this study is the analysis of pertussis incidence data—along
with demography and vaccination histories—from around the world. Jackson et al. recently re-
viewed such data and showed that global pertussis epidemiology is complicated and by no
means follows the same patterns and explanations as the U.S. [38]. However, the authors of the
review do note that the issue of the switch from the wP to the aP vaccine may be sufficiently
specific to allow investigation of its impact upon global trends.
Transmission models with a realistic representation of the natural history of infection and
immunity, and population contact processes, fitted to data with statistically rigorous methods,
are useful tools to quickly investigate increases in disease incidence, whether they occur within
the U.S. or globally [39–41]. Pertussis epidemiology is complex and disease incidence is non-
linearly related to vaccine coverage. With doubt around the efficacy and duration of protection
of the acellular vaccine, modeling is an essential tool to help us better understand the changing
epidemiology of pertussis.
Table 3. State variables (population compartments) andmodel parameters for the model
investigated.
Symbol Description Value
Population compartments (state variables)
S Susceptible
I1 Primary infection
I2 Secondary (or greater) infection
R Recovered from infection (whether primary or secondary)
V Vaccinated
D Reported cases of pertussis
Model parameters
λ(t) Force of infection at time t (this subsumes the model
parameter β (known as the transmission parameter)
which is estimated by the model-ﬁtting procedure)
Varies in value depending upon number
of individuals infected (Per capita per
year)
Τ Rate of recovery from primary or secondary infection 24 per year (i.e. duration of infection is
approx. 1/24 years = 16 days)
Δ Rate of loss of immunity following natural infection Estimated here (see Table 2)
Γ Rate of loss of immunity following vaccination Estimated here (see Table 2)
Σ Relative rate of acquisition of secondary to primary
infection
Estimated here
Η Relative infectiousness of secondary infections Estimated here
p1, p2 Rate at which infected individuals report disease Estimated here
doi:10.1371/journal.pcbi.1004138.t003
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Methods
We constructed a compartmental mathematical model of the natural history and population
transmission of B. pertussis infection in the United States, in which the population transitions
between three states of infection: susceptible, infected, and recovered from a prior infection. In-
fected individuals can be either primary-infected or infected more than once (see Fig 5, Table 3
and ‘Model structure details’ below). The model also accounts for the annual aging of the popu-
lation: the time-dependent birthrates and deathrates are used for the U.S. (obtained from [42]).
The birth and deathrates prior to the analysis period of the study were fixed at the earliest val-
ues available, namely those of 1950. Mixing between age-groups is incorporated according to a
European diary-based contact study (used in the absence of a suitable U.S. alternative [43]).
Vaccination is included as a process by which a proportion of the susceptible population at
a particular age is transferred to either the recovered compartment or a vaccinated compart-
ment (i.e. all-or-nothing vaccination protection for each dose). In both of these compartments,
individuals have developed a protective immune response which decreases the probability of
infection but eventually wanes. This vaccinated proportion may be thought of as coverage x
vaccine efficacy and is equal to the protected proportion of the population with each dose. An-
nual vaccination coverage levels were obtained from the National Immunization Survey and its
predecessor surveys [45].
The U.S. pertussis vaccine schedule recommends three doses to infants—at two, four and
six months and two further doses: one at 18 months and the fifth and final dose between four
and six years of age. We model the first three doses as a single removal of susceptible infants six
months following birth (as an approximation of the building immunity due to the first three
doses), the 18 month dose as two separate removals, each with one half of the overall coverage,
at one and two years of age and, similarly, the final dose as two separate removals at four and
five years of age. The 18 month and four to six year doses are represented as double doses to
capture a fairly wide range of times at which vaccine is administered to children across the
whole population. The whole-cell vaccine is first applied to the model population in the simula-
tion year 1947 and a switch is made to the acellular vaccine for the final two doses in 1992 and
then to the entire schedule in 1998. A Tdap booster vaccine is introduced to those aged 12
years in the model, in 2005, with coverage levels given by recent surveys [46–51].
Disease is reported at a rate, p, the proportion of cases captured by NNDSS. This rate was per-
mitted to change once in the time period modelled, to partially account for (i) a possible change
in the sensitivity with which cases are found over time, and (ii) increased reporting associated
with greater awareness of pertussis among patients and physicians. We also allow for some level
of spatial and temporal heterogeneity in the reporting rate by modelling p as drawn from a Beta
probability distribution (see Statistical details); this allows for a single average value of the report-
ing rate to be estimated for each of the two time periods, but for the uncertainty in this value to
be quantified. Only those in the primary-infected compartment (I1, Fig 5) were counted as disease
cases; this is a simplification, but one that is justified by recent studies which show that second-
ary-infected or vaccinated non-human primates had more limited disease when reinfected [52].
Models were fitted in a Bayesian framework to annual incidence data, summed over the
whole U.S. population (in cases per 100,000 persons), from 1950–1989, and to age-stratified in-
cidence data obtained from NNDSS for the years 1990 to 2009. The fitting was performed
using Markov Chain Monte Carlo (MCMC) methods, which find an ensemble of model pa-
rameters that fit the data and allow a credible interval for each of these parameters to be deter-
mined. The chains were run to 100,000 steps during equilibration and 50,000 to sample the
posterior parameter distributions. Sensitivity of the parameter estimates was explored by per-
forming MCMC separately using different subsets of the data.
A Change in Efficacy and Duration of Pertussis Vaccine
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Several candidate models were constructed, each with the basic structure given in Fig 5 but
including or excluding specific components, and their parameters were fitted to the data (see
Table 1). These model components included possible changes in (i) duration of protection be-
tween whole-cell vaccination and natural infection; (ii) vaccine efficacy and (iii) duration of
protection between the whole-cell and acellular vaccine. The candidate models were compared
to determine the simplest and most biologically compelling explanation of the observed varia-
tions using the Deviance Information Criterion (DIC), a measure that accounts for both good-
ness-of-fit as well as model complexity [53] (the higher the value, the better the fit to the data).
Misegades et al [22] performed a case-control study in California in 2010 to determine the
vaccine effectiveness (VE)(of the full course of 5 doses of DTaP for each of 5 years following
the delivery of the final dose. In order to further constrain our parameter selections and values,
we used our models to simulate this study and fitted the resulting VE values to those found by
Misegades at each of the corresponding times. Misegades found that the VE decreased from
98% to 82% in 4 years following the final of five doses. As well as measuring our model-based
VE over the same period, we used the same method to estimate VE during a period when the
course of doses consisted entirely of the whole-cell vaccine; we selected 1990 for this purpose.
Model structure details
The mathematical model we constructed has an age-structured susceptible-infected-recovered
(Si, I1i, Ri) structure (the subscript i, corresponds to one of 35 age-groups), but with the addi-
tion of a second infected compartment (I2i) to account for those who have been previously in-
fected. The mixing matrix β(i, j) represents the product of the contact rate (obtained from the
‘POLYMOD’ diary study of contact patterns in Great Britain (GB) [43]) and the transmission
probability per contact between individuals in age-groups i and j. Individuals in state I2i have
an infectiousness value of η compared with those in state I1i, and the relative susceptibility to
infection of those in Ri (the ‘recovered’ state) compared with those completely susceptible. Vac-
cination occurs with the DTP vaccine with whole-cell pertussis component by shifting individ-
uals into compartment V1i and into V2i for the DTaP and Tdap vaccines (the main text
simplifies this flow into a single compartment Vi so as not to clutter the exposition). The equa-
tions corresponding to the model flow diagram (Fig 5, Table 3) are given below:
dSi
dt
¼ Si:ðli þ miÞ þ a:Ri
dI1i
dt
¼ Si:li  ðtþ miÞ:I1i
dI2i
dt
¼ sli:Ri  ðtþ miÞ:I2i
dRi
dt
¼ t:ðI1i þ I2iÞ  ðdþ sli þ miÞ:Ri
dV1i
dt
¼ ðgþ miÞ:V1i
dV2i
dt
¼ ðgþ miÞ:V2i
where the force of infection; li ¼
X35
j¼1
bði; jÞ: I1j
Nj
þ Z: I2j
Nj
 !
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Statistical details
Pertussis case count data from NNDSS were aggregated into annual counts for each age group
so that yi (t) is the number of pertussis disease cases for age group i in year t. Our mathematical
model outputs were also aggregated into annual counts for each age group i, so that xi (t) was
the model-derived case count for age group i, during year t. These model-derived case counts
are functions of the model structure and parameters, so that they might be better expressed as
xi (t|θ,M), where θ represents the parameter vector for modelM.
Since the pertussis cases counted by NNDSS may be a proportion of the true number (and
the output of the natural history epidemiological model is designed to simulate the true num-
ber) we can say that the observed number of cases follows an observation model so that annual
counts of pertussis cases (obsi (t)) are governed by a binomial distribution:
obsiðtÞ ¼ Binomialðxiðtjy;MÞ; ðtÞ; piðtÞÞ
The proportion of individuals with disease who report it (pi (t)) may vary over time in a
number of ways (e.g. linear/nonlinear increase or decrease) but here we account for this tempo-
ral uncertainty in the simplest way, by allowing the value of pi (t) to change once during the
course of a simulation run (i.e. it has one value prior to a time T and a different value after this
time) so that:
piðtÞ ¼
p1; t  T
p2; t > T
(
The binomial log-likelihood of the data given these considerations is:
Log Likelihood ¼X
i
X
t
lnðxiðtÞ!Þ  lnðyiðtÞ!Þ  lnððxiðtÞ  yiðtÞ!ÞÞ þ yiðtÞ:lnðpiðtÞÞ þ ðxiðtÞ  yiðtÞÞ:lnð1 piðtÞÞ
This LL sum can now be used as an objective function for our Markov Chain Monte Carlo
scheme, to fit our model parameter values so that model outputs match the NNDSS data. How-
ever, we find that it can be excessively difficult to explore the parameter space productively (i.e.
moving from regions of poorer to relatively better fits to the data) since the binomial likelihood
surface can take on high (i.e. better fitting) values in very small (and therefore very hard to lo-
cate) regions of parameter space. To attempt to remedy this problem (as well as to account for
a more general degree of uncertainty in the disease reporting rate), we introduce into our ob-
servation model a further layer of uncertainty such that the proportion of individuals reporting
disease is drawn from a Beta distribution, which has two parameters,
pðpiðtÞÞ ¼ Betað/ ðtÞ; bðtÞÞ
where the Beta distribution’s parameter values are time-dependent in the same way as we posit-
ed above i.e.:
/ ðtÞ; bðtÞ ¼ /1; b1 t  T/2; b2 t > T
(
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Using this structure for the reporting rate component of the observation model, we can re-
calculate the likelihood of a particular dataset given the model (removing the subscripts for
simplicity of presentation):
likehood ¼
Z 1
0
Binomialðx; pÞ:pðpÞ:dp
This integral allows us to compute an average likelihood allowing for the entire distribution
of the reporting rate p, given its Beta distribution. Because the Beta and Binomial distributions
are conjugate, the integral is straightforward.
likehood ¼
x
y
0
@
1
A
Bð/ ðtÞ; bðtÞÞ
Z 1
0
Binomialðx; pÞ:pðpÞ:dp
¼
x
y
0
@
1
A
Bð/; bÞ
Z 1
0
pyþ/1:ð1 pÞxyþb1:dp
Where B(/, β) is the normalizing constant for the Beta probability distribution. The inte-
grand can be seen to be the probability density function of the Beta distribution Beta(/0, β0)
with the adjusted (or ‘renormalized’) parameter values, so that:
/0 ¼ yþ /; b0 ¼ x  y þ b
So the integral above is the normalization constant of the Beta distribution (which is re-
ferred to as the Beta function, itself comprised of a set of gamma functions, see below) with the
adjusted parameters. The likelihood therefore becomes:
likelihood ¼
x
y
0
@
1
A:Bðyþ /; x  y þ bÞ
Bð/; bÞ
¼
x
y
0
@
1
A:Gðyþ /Þ:Gðx  y þ bÞ:Gð/ :bÞ
Gð/Þ:GðbÞ:Gððyþ /Þ:ðx  y þ bÞÞ
And for all of the data points, the log-likelihood becomes:
LL ¼
X
i
X
t
"
ln
xiðtÞ
yiðtÞ
 !
þlnðGðyiðtÞþ/ðtÞÞÞ þ lnðGðxiðtÞ  yiðtÞ þ bðtÞÞÞ þ lnðGð
/ ðtÞ:bðtÞÞÞ lnðGð/ ðtÞÞÞ  lnðGðbðtÞÞÞ  lnðGððyiðtÞþ / ðtÞÞ:ðxiðtÞ  yiðtÞ þ bðtÞÞÞÞ
#
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Supporting Information
S1 Text. S1 Text includes a brief description of alternative model structures that have been
investigated in the recent literature; a table outlining precisely which parameters are al-
lowed to alter and which are fixed for each of the models we investigate; a series of plots
outlining the best-fitting model’s fit to the age-dependent incidence of disease cases for
each of the years between 1990 and 2009; and a model-based simulation of the case-control
study outlined in the main article, showing the gradual effect of an aging cohort of individ-
uals who have been entirely vaccinated with the DTaP rather than the DTP vaccine.
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